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 Tumor necrosis factor (TNF)-Receptor Associated Factors (TRAFs) are a 
family of signal transducer proteins. TRAF6 is a unique member of this family in 
that it is involved in not only the TNF superfamily, but the toll-like receptor 
(TLR)/IL-1R (TIR) superfamily. The formation of the complex consisting of 
Receptor Activator of Nuclear Factor κ B (RANK), with its ligand (RANKL) 
results in the recruitment of TRAF6, which activates NF-κB, JNK and MAP 
kinase pathways. TRAF6 is critical in signaling with leading to release of various 
growth factors in bone, and promotes osteoclastogenesis. TRAF6 has also been 
implicated as an oncogene in lung cancer and as a target in multiple myeloma. In 
the hopes of developing small molecule inhibitors of the TRAF6-RANK 
interaction, multiple steps were carried out. Computational prediction of hot spot 
residues on the protein-protein interaction of TRAF6 and RANK were examined. 
Three methods were used: Robetta, KFC2, and HotPoint, each of which uses a 
different methodology to determine if a residue is a hot spot. These hot spot 
predictions were considered the basis for resolving the binding site for in silico 
high-throughput screening using GOLD and the MyriaScreen database of 
drug/lead-like compounds. Computationally intensive molecular dynamics 
simulations highlighted the binding mechanism and TRAF6 structural changes 
upon hit binding. Compounds identified as hits were verified using a GST-pull 
down assay, comparing inhibition to a RANK decoy peptide. Since many drugs 
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fail due to lack of efficacy and toxicity, predictive models for the evaluation of 
the LD50 and bioavailability of our TRAF6 hits, and these models can be used 
towards other drugs and small molecule therapeutics as well. Datasets of 
compounds and their corresponding bioavailability and LD50 values were curated 
based, and QSAR models were built using molecular descriptors of these 
compounds using the k-nearest neighbor (k-NN) method, and quality of these 
models were cross-validated.  
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Introduction:  
 TNF-Receptors Associated Factors (TRAFs) are a family of adapter proteins, 
originally identified in humans and rodents by their association to the cytoplasmic tails of 
different members of the TNF-Receptor (TNFR) family [1]. In mammals, TRAFs 
contribute to the regulation of as many as 20 TNFRs [2-5]. TRAFs are primarily involved 
in the signals regulating the inflammatory and immune systems, as well as regulating 
apoptosis. There are seven members (TRAF1 through TRAF7) of the TRAF family, and 
all but TRAF7 are characterized by a conserved, 180 residue fold called the TRAF 
domain (TD). It is the TD that supports the interaction with TNFRs and other adapter 
proteins; as one would expect, TRAF7 does not directly interact with TNFRs [3, 6]. The 
TRAF domain has an α-helix segment followed by eight anti-parallel β-strands (also 
called the TRAF-C domain) which fold into a β-sandwich structure, and usually 
oligomerizes as mushroom-shaped trimers that are stabilized by the coiled-coil 
interactions between the α-helices of each TD monomer [2, 6, 7]. As for the other 
structural features in TRAFs, all contain one to seven zinc finger domains [8] and all but 
TRAF1 have N-terminal RING-finger (Really Interesting New Gene) domain. All 
mammalian TRAFs localize to the cytoplasm except TRAF4 which is found in the 
nucleus. 
Among the TRAF family members, TRAF6 has distinct features and 
physiological functions that are not shared in other TRAFs. TRAF6 was first identified 
by a yeast two-hybrid screen using the cytoplasmic tail of CD40 as bait and 
independently by expressed sequence tag (EST) screening [9, 10]. Protein sequence and 
phylogenetic studies revealed that is the older and less conserved TRAF family member 
despite maintaining all of the structural characteristics of the other members of the 
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family. TRAF6 shares the smallest amount of homology to the prototypical TRAF 
domain, and has the most divergent TRAF-C domain [11].  The unique function of 
TRAF6 is primarily determined by its TRAF-C domain, which does not share the same 
peptide motif interactions as TRAF1, -2, -3 or -5 [12-14]. TRAF6 binds to a consensus 
sequence of: xxPxExx(Ac/Ar) (where the last residue is aromatic or acidic), whereas 
TRAF1, -2, -3, or -5 bind to a (P/S/A/T)x(Q/E)E motif [2, 8, 15-17]. Another 
distinguishing feature of TRAF6 from other TRAFs is its ability to transduce signals 
from the TLR/IL-1R superfamily as well as the TNFR superfamily [18]. TRAF6 does not 
have direct interaction with members of the TLR/IL-1R family. Instead, recruitment of 
adaptors occur upon its activation, such as the myeloid differentiation factors 88 
(MyD88), toll/interleukin-1 receptor adaptor protein (TIRAP), and TRIF-related adaptor 
molecule (TRAM) [1]. Since TRAF6 is a central hub for a wide variety of signals, it is 
not surprising that it can regulate an array of physiologic processes, including adaptive 
and innate immunity, bone metabolism, and the development of structures such as 
mammary glands, central nervous system, and the skin. 
TRAF6 has an N-terminal RING-finger domain, followed by four zinc-finger 
domains, the coiled-coil domain, and finally the C-terminal TRAF domain (Figure 1). 
Again, this TD is comprised of eight anti-parallel β-strands that form a stable sandwich 
structure, and are preceded by a single α-helix segment. The unique sequence specificity 
of TRAF6 does not overlap with other TRAF members; it interacts directly with a subset 
of the TNFR superfamily, two such examples of which are CD40 and Receptor activator 
of nuclear factor-kappa B (RANK, also known as TRANCE-R).  
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Figure 1. Domains of the TRAF6 protein.  
The TRAF6 Protein consists of four parts: a Really Interesting New Gene (RING) 
finger domain, four zinc finger (Zn finger) domains, a coiled-coil domain, and a C-
terminal TRAF-C domain. The RING domain acts as an E3 ubiquitin ligase. 
In addition to the signal transduction of the TNFR superfamily, TRAF6 is also a 
significant transducer for the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) 
superfamily. Within the IL-1Rs and TLRs resides a component called the TIR domain; it 
is this domain that recruits a family of TIR-domain containing signaling proteins, 
including MyD88, Mal/TIRAP, TRIF, and TRAM [19]. As a result, these signaling 
complexes recruit Serine/Threonine kinases in the IRAK family (IRAK1, IRAK2, IRAK-
M and IRAK4), which then interact with TRAF6 to activate downstream signal 
transduction [20-23].  
While TRAF6 mediates signaling in a wide spectrum of cellular physiological 
functions, the interaction of TRAF6 and RANK are of special interest. The pair of RANK 
and RANK ligand (RANKL) is essential for bone remodeling by regulation of osteoclasts 
development and function [24] , mammary gland development [25] and lymph node 
organogenesis [26, 27]. Also worthy of mention is the fact that the RANK/RANKL pair 
controls the incidence and onset of progestin-driven breast cancer [28], and plays a 
significant part in migration and metastatic behavior of cancer cells, acting as a fertile 
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soil for metastatic tumors going to the bone [29]. When the RANK/RANKL complex is 
formed, TRAF6 is recruited, which then results in the activation of the NF-κB 
transcription factor, as well as members of the mitogen-activated protein (MAP) kinase 
family, which include: MAPK, c-Jun N-terminal kinase (JNK), and p38. TRAF6-
deficient mice have a defect in osteoclastogenesis, and develop osteopetrosis as a result 
[30-32]. TRAF6 is the critical adapter in RANK-mediated osteoclast differentiation, and 
the TRAF6/RANK interaction is a potential target for inhibition in the treatment of 
various bone diseases, and might have implications in the areas of breast/lymph node as 
well.  
New evidence from copy number alterations shows that TRAF6 is an oncogene in 
lung cancer. Overexpression of TRAF6 results in tumor formation and malignant 
transformation of fibroblasts, and RNA interference (RNAi)-mediated knockdown of 
TRAF6 decreases adenocarcinoma in two lung cell lines that have TRAF6 amplification 
[33]. In these two lung cell lines, RAS required TRAF6 for its oncogenic capabilities. 
This finding provides an explanation for constitutive NF-κB activation in RAS-driven 
cases of lung cancer. 
TRAF6 has been shown to play a major role in the signal transduction of 
inflammation, cell survival and proliferation. Down-regulation of TRAF6 is beneficial in 
a therapeutic setting, since there have been many implications of TRAF6 in different 
disease states. TRAF6/RANK and their neighboring binding partners have been shown to 
contain valid, druggable targets in two notable areas: The RANK/RANKL interaction and 
TRAF6 decoy peptides. The RANK/RANKL portion of this pathway has seen 
monoclonal antibodies against it in the form of Denosumab, which is an anti-RANKL 
human monoclonal antibody developed by Amgen for use in the treatment of bone 
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loss/destruction due to rheumatoid arthritis, or metastatic cancers [34]. It is the first 
RANKL inhibitor to be approved by the FDA, and it is showing promising results for 
multiple myeloma with bone metastases [35]. Although germline deficiencies in 
RANK/RANKL show strong B cell defects and it was suggested that RANKL inhibition 
could trigger immunologic side effects, B cell specific RANK knockout mice in fact did 
not show obvious direct defects in B cell physiology or development [36]. The other 
notable area is that of cell-permeable peptides that bind to TRAF6 (TRAF6 decoy 
peptides, referred to as T6DP) and have been developed that can target the 
TRAF6/binding peptide interaction, and these have been shown to prevent RANK 
signaling [15]. These peptides display specificity for the TRAF6-binding domains, and 
the core motif (RKIPTEDEY) inhibited RANKL-mediated osteoclastogenesis and bone 
resorption. RANKL-dependent activation of NF-κB undergoes a dose-dependent 
inhibition upon pre-treatment with these decoy peptides, and primary mouse monocytes 
differentiation into functional bone resorbing osteoclasts  were blocked as well [37]. 
While these peptides are effective in blocking the interaction in experimental protocols, 
their large size and potential sensitivity to endopeptidases renders them unsuitable as 
clinical therapeutic agents. These decoy peptides might find future use when used in 
liposomal or nanoparticle delivery techniques. 
TRAF6’s role and mechanism in signaling in its diverse pathways becomes clear 
when one examines its ubiquitin ligase activity. Ubiquitin ligases attach a small protein 
called ubiquitin to target proteins; this ubiquitin can then induce either degradation of the 
target protein (via the proteasome) or can promote interactions with other proteins that 
result in signal transduction. Two main factors of ubiquitination allow for the 
discrimination between degradation and signal transduction: the number of ubiquitin 
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proteins added (monoubiquitination versus polyubiquitination), and which specific lysine 
residue that gets modified. Lysine48 (K-48) linked ubiquitination is recognized by the 
26S proteasome and this ubiquitination triggers the protein degradation. Lysine63 (K-63) 
linked ubiquitination is an important post-translational modification that can facilitate 
various biological processes, including: activation of kinase signaling, endocytosis of 
cellular receptors, protein localization and trafficking, and repair of damaged DNA [38-
40]. On TRAF6, the intact RING domain and the first zinc finger are required for K-63 
auto-ubiquitination of TRAF6, and subsequent activation of downstream activation of 
targets such as: IL-1, LPS, IKK, JNK, NF-κB, and osteoclasts differentiation via RANKL 
signaling [41-43]. A recent crystal structure has shown the RING domain interacts with 
the ubiquitin-conjugating enzyme (E2) called Ubc13, and that the first zinc finger has a 
structural role in binding to Ubc13 [44]. Another significant finding in the ubiquitin 
pathway is that Akt (the serine/threonine kinase, also called protein kinase B) 
ubiquitination is triggered by TRAF6 E3 ligase activity. TRAF6 adds ubiquitin to Akt 
and induces Akt ubiquitination in vitro and in vivo and is essential for Akt ubiquitination 
and localization to the membrane where Akt is then phosphorylated and activated [45]. 
This ubiquitination of Akt occurs via the K-63 pathway and does not trigger Akt 
degradation. Other kinases that are activated by TRAF6 K-63 ubiquitination are: 
transforming growth factor-β-activating kinase 1 (TAK1) [46, 47], mixed linage kinase 3 
(MLK3) [48], and interleukin-1 receptor-associated kinase (IRAK1) [49]. 
TRAF6 is a prime drug target candidate to inhibit using rational drug design. To 
date, there are no known small molecule inhibitors of TRAF6 in the C-terminal region. 
This is surprising, as the above data clearly show that TRAF6 is a highly significant and 
valid target for the treatment of bone-related diseases. The discovery of TRAF6 as an 
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oncogene makes its use as a target even more appealing. The availability of high-
resolution crystal structures of the C-terminus of TRAF6 bound to both RANK and CD-
40 and the ineffectiveness of peptide-based treatments calls for the use of small molecule 
inhibitors through structure-based drug design. The effectiveness of potential hits that are 
discovered by this method can have their effectiveness compared to decoy peptides as a 
positive control. From the publication describing the crystal structures, mutational 
analysis was carried out to indicate which residues were required for binding to binding 
peptides. Three residues on TRAF6 have been shown to abolish binding to CD40 (a close 
analog to RANK) that shares the core motif as RANK; Arg392, Phe471, and Tyr473 
(Figure 2); these residues can be considered hot spot residues [15]. These residues are a 
good starting point for which to carry out structure-based drug design, as small molecule 
inhibitors can interact with these hot spots and prevent formation of the TRAF6/RANK 
complex. Using small molecules to inhibit the formation of protein-protein interactions is 
a relatively recent technique, and hot spots have been used successfully to disrupt and 
inhibit protein-protein interactions for a multitude of targets [50]. 
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 Figure 2. Structure of TRAF6 (green) bound to RANK peptide (magenta).  
 
Residues experimentally determined to be hot spots (Arg392, Phe471, and Tyr473) 
are displayed as green sticks. Hydrogen bonds between RANK and TRAF6 
displayed as dashed magenta lines. Figure generated in PyMOL. 
 
In the current study, I will outline the steps that will aid in bringing a TRAF6 
small molecule inhibitor closer to clinical relevance. In the hopes of developing TRAF6 
as a valid target for small molecule therapeutics, computational prediction of hot spots 
was carried out on the protein-protein interaction of TRAF6 and its binding peptides. 
Three methods were used: Robetta, KFC2, and HotPoint, each of which uses a different 
methodology to determine if a residue is a hot spot. These hot spot predictions were 
considered the basis for resolving the binding site for TRAF6 in silico high-throughput 
screening. Screens on the crystal structure of TRAF6 in complex with RANK will be 
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carried out using combined docking programs and our database of 10,000 drug/lead-like 
compounds. Flexibility of side-chains that contribute significantly to the binding will be 
considered. During hit selection, chemical diversity and drug-like properties will be 
considered. Computationally intensive molecular dynamics simulations will be conducted 
using GROMACS to determine the binding mechanism and TRAF6 structural changes 
upon hit binding. Compounds identified as hits will be verified using a GST-pull down 
assay, comparing inhibition to a RANK decoy peptide.  
Since many drugs fail due to lack of efficacy and toxicity, predictive models for 
the evaluation of the LD50 and bioavailability of our TRAF6 hits were developed, and 
these models can be used towards other drugs and small molecule therapeutics as well. 
Datasets of compounds and their corresponding bioavailability and LD50 values were 
curated, and predictive QSAR models were built using molecular descriptors of these 
compounds using the k-nearest neighbor (k-NN) method, and quality of these models 
were cross-validated using leave-one-out cross validation. 
 
Methods:  
1. Computational Hot Spot Predictions of TRAF6  
 Since the three hot spots of the TRAF6/binding peptide interaction have been 
described previously, computational prediction tools were used and compared to the 
actual results, in an attempt to validate these predictions. Additionally, these predictions 
can predict residues that are weak hot spots, or calculate potentials of residues that were 
not biologically tested; these predictions were then used to guide the virtual screening. 
The computational tools were: Robetta [51], an energy based computational alanine 
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scanning technique, HotPoint [52], a simple empirical model based on accessible surface 
area, and KFC2 [53, 54], a knowledge-based and machine learning approach. 
2. Preparation and Analysis of Target Receptor 
 The crystal structures of the C-terminal region of TRAF6 in complex with the 
RANK and CD40 polypeptide were obtained from the Protein Data Bank [55] (1LB5 and 
1LB6, respectively) [15]. These crystal structures display residues Gln347 to Thr501 of 
TRAF6 (the TRAF6 sequence has 522 residues in total). 1LB5 was selected as the target 
for virtual screening since it has the RANK peptide bound to the TRAF6 structure, and 
the A chain was analyzed in complex with the B chain (RANK peptide) for virtual 
screening. Structural water molecules were not considered to be significant to binding, 
and these water molecules along with the B chain were removed from this 1LB5 structure 
using PyMOL [56].  
3. Chemical Library Selection 
 The dataset of compounds to be screened was the 10,000 compound MyriaScreen 
Diversity Collection from Sigma-Aldrich in collaboration with TimTec. This was 
selected for its high diversity and good drug-like and lead-like properties, as well as the 
commercial availability of high-purity compounds. MyriaScreen was assembled from an 
original pool of 300,000 Sigma-Aldrich and TimTec compounds, and TimTec’s 
proprietary software was used to filter this original pool on the basis of diversity. Then, 
additional filters were set to consider MW (>225 and <600), cLogP, H-acceptors, H-
donors, and rotatable bonds. 99.04% of compounds in the MyriaScreen collection satisfy 
all four rules of the Lipinsky rule of 5 [57].  
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 The MyriaScreen chemical dataset (in .sdf file format) was minimized with root 
mean square gradient of 1 x10-6 in MOE software from Chemical Computing Group [58] 
based on MMFF94x (Merck molecular force field 94x) [59] and partial charges. The 
MMFF94x force field is quite suitable for small molecules [60]. Minimization is required 
to reach optimal energy levels for ligands before submitting them to virtual screening. 
4. Virtual Screening 
 The MyriaScreen dataset was docked using GOLD from Cambridge 
Crystallographic Data Centre (CCDC) [61, 62]. Hydrogen atoms were added using 
GOLD program before docking was performed. The protein was treated as rigid, with no 
amino acid side chains considered flexible. The binding site residues were manually 
selected, and formed the cavity file. The residues selected were based on their proximity 
to the RANK peptide co-crystallized with TRAF6: Arg392, Phe410, Met450, Leu456, 
Leu457, Ala458, Phe459, Pro468, Lys469, Gly470, Phe471, Gly472, Tyr473, and 
Val474. Ten genetic algorithm runs were selected for each ligand, and search efficiency 
was set at 200% (double the default efficiency). Early termination of the docking of a 
given ligand was performed (meaning GOLD advanced to the next ligand) if the top 3 
solutions/conformations of a given ligand were within 1.5Å of each other. Although all 
scores were kept, only the top 2000 GoldScore solutions/conformations were written out 
as an SDF file. 
5. Processing of Results 
 The results from the docking were then clustered based on structural MACCS 
(Molecular ACCess System) fingerprints using MOE fingerprint clustering. The top 2000 
GoldScored compounds were entered into MOE, and their molecular fingerprints were 
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calculated. The metric used was the Tanimoto coefficient. Similarity and overlap were set 
at 80% to cluster similar compounds together. The result of this clustering was that 
compounds that shared 80% of their total molecular features with other compounds were 
merged into one cluster. For each cluster, the compound with the highest GoldScore in 
that cluster was selected as the representative for that cluster, and the others in that cluster 
were discarded. This clustering output contained 1619 compounds, indicating that 381 
compounds had at least 80% similar molecular features but lower GoldScores than other 
compounds in a single cluster, and these 381 were discarded. 
 
6. Selection of Compounds for Biological Testing 
 From these 1,619 ligands, the top 300 ligands were selected for individual 
molecular visualization and consideration. Each of the 300 ligands were individually 
visualized (using PyMOL) in their docked conformation on TRAF6, and compounds 
were selected for purchase and experimental testing via both pull-down and fluorescence 
polarization assays.  
 Three main criterions were considered sequentially in this final selection process. 
The first criterion was the degree to which the ligands’ conformation occupied the 
interaction site between TRAF6 and RANK. If the ligands’ conformation primarily 
existed outside of the interaction site, it was no longer considered a candidate. Second, 
the following qualities: conformation, binding affinity, and resulting “fit” within the 
TRAF6 binding site (compared to the corresponding RANK residues) were considered. 
Each ligand, given its orientation in the docked position, was evaluated on its ability to 
potentially block the binding of the RANK peptide. Along with these potential blocking 
effects, we also considered the potential binding affinity of the ligand in its pocket. This 
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included qualities such as hydrogen bonds, static and aromatic effects that could be 
formed from the ligand and TRAF6. The third and final consideration was the 
distinctiveness of the molecular scaffold when compared to other ligands in the result. 
The ligands were partitioned into “classes” based upon the individuality of their 
underlying scaffold and how this scaffold was oriented in the binding site. Ligands that 
shared a similar scaffold and orientation were considered to be in the same class, and 
would then share the same class number. We then assigned a “priority” to each molecule 
which was an aggregate of the second and third factors (conformation in the pocket and 
distinctiveness). This priority was listed as: low, medium or high. The priority then 
became similar to a degree of confidence for each ligand; compounds with “high” 
priority were regarded as most likely to yield good biological activity, and should be 
tested over the other low and medium confidence ligands.  
 
7. Biological Testing 
 To test potential hits for their ability to inhibit TRAF6 functions, a GST-RANK 
competitive inhibition assay was used. The procedure outlined here was provided by and 
performed primarily by Professor Bryant Darnay from the department of Experimental 
Therapeutics in MD Anderson Cancer Center. Human embryonic kidney (HEK) 293 cells 
that stably express FLAG-tagged TRAF6 were harvested and lysed in lysis buffer (20 
mM Tris, pH 7.4, 250 mM NaCl, 1 mM DTT, 1 mM sodium orthovanadate, 2 mM 
EDTA, 1% Triton X-100, 2 µg/ml leupeptin, and 2 µg/ml aprotinin 20 mM) for 30 min 
on ice.  The cell lysate was centrifuged for 15 min and the supernatant was collected and 
protein estimated.  Equal amounts (150-200 µg) of protein lysate in binding buffer (20 
mM Tris, pH 7.4, 150 mM NaCl, 1 mM dithiothreitol, 0.1% Nonidet P-40 and 2 mM 
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EDTA) were mixed with the indicated compounds or TRAF6 decoy peptide 3 (T6DP3) 
and allowed to rotate for 1 h at 4C, after which the samples were centrifuged for 5 min.  
The supernatant was then mixed with bacterial purified GST-RANK-(340-358) bound to 
glutathione-agarose beads for 2 h at 4oC with end-over-end rotation.  The samples were 
washed three times in binding buffer and two times in low salt buffer (20 mM TRIS pH 
7.4, 25 mM NaCl, and 1 mM DTT).  Bound proteins were then eluted in SDS-sample 
buffer and boiled for 5 min, subjected to SDS-PAGE, and immunoblotted with anti-
FLAG [37]. 
 
8. Molecular Dynamics simulations 
 In order to describe the interactions of the hits that were identified in the 
screening, I performed molecular dynamics (MD) simulations of the three hits in 
complex with TRAF6, as well as a simulation of the TRAF6/RANK complex as a 
comparison. GROMACS (version 4.5.3) was the software used, and explicit water was 
used for these simulations [63, 64]. The force field selected was the GROMOS96 43a1 
official distribution [65]. A cubic water box was created for the protein-ligand complex, 
and the distance between the solute and the box was set at 0.9 Å. Charges were added to 
neutralize the system to a formal charge of zero, and then the system was minimized 
when the maximum force of the system was less than 10.0 kJ/mol. PME (Particle mesh 
Ewald) algorithm was used for the long-range electrostatics for all simulations. For the 
NVT (moles, volume, temperature) and NPT (moles, pressure, temperature) equilibration 
the protein and ligand were considered as one entity (coupled together), and the ions and 
water were also coupled together as one entity. This coupling was necessary, as the 
system exploded (became highly unstable) not long after production MD started when 
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this coupling was not present. Temperature was set at 298K, and the modified Berendsen 
thermostat and Parrinello-Rahman were used for NVT and NPT coupling, respectively. 
Periodic boundary conditions were set for x, y, and z directions. For each of these 
production MD simulations, the bound conformations from GOLD were used as the 
starting input, and the PRODRG server was used to generate topology (.itp) files for each 
of the ligands [66]. All simulations were run for 20 nanoseconds. Jobs were run by 
remote SSH terminal from my workstation into the Lonestar computing cluster in the 
Texas Advanced Computing Center (TACC), using 144 cores [67]. Results were 
extracted using VMD, and were analyzed using PyMOL [56, 68]. 
 
9. LD50 Predictive QSAR Modeling 
 A dataset of 7385 compounds and LD50 values for oral rat exposure was collected 
from a previous study by Hao Zhu et al. who were attempting to achieve the same 
endpoint; the details of how that dataset was collected are described in the following 
section [69]. A dataset of more than 8000 compounds and corresponding LD50 (oral rat 
exposure) from the ChemID plus database was collected, and the structures of these 
compounds was verified using an method discussed by Young et al. [70].  Zhu’s group 
removed the inorganic, organometallic compounds, salts, and compound mixtures. They 
also converted the LD50 values from mol/kg to log(mol/kg) values according to standard 
QSAR practices [69]. Various descriptors were calculated including those from the 
Dragon software v5.4 [71], MOE [58], and cxcalc from ChemAxon [72]. These 
descriptors were then used with the kNN-QSAR method to provide the models [73]. The 
kNN-QSAR method was used to generate the predictive models. 
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10. Bioavailability Predictive QSAR Modeling 
 A dataset of 809 compounds was collected from two publications: 768 
compounds from Hou et al. and from Veber et al., these two datasets were merged 
despite having many similar entries [74, 75]. The values were often taken from the 
literature; single values were recorded as-is, whereas when a range of values was 
reported, a simple average was used as the percent bioavailability [76]. For example, if a 
value was reported as 0-20% bioavailability in Goodman and Gilman’s, the value used 
was considered 10%. Descriptors for this data set were calculated in an identical manner 
to the LD50 data set, and the kNN-QSAR method was also used to generate the predictive 
models. 
 
Results: 
1. Computational Hot Spot Predictions of TRAF6 - Results 
 Robetta uses a simple physical model and a computational alanine scanning 
technique that includes various energy and chemical bonding parameters such as: 
Lennard Jones interactions, packing and solvation terms, and hydrogen bonding to 
calculate free energy [51]. Computational alanine scanning involves mutation of a given 
residue involved in a protein-protein interaction to alanine (a non-reactive and non 
charged side chain) of one of the interacting proteins, and computing the resulting change 
in binding energy of the interface. If this mutation results in a significant decrease in the 
binding constant (typically tenfold or greater), this residue is considered a hot spot [77]. 
Robetta mutates the residue to alanine for each residue, and then it locally repacks other 
residues in the structure within 5Å of the mutant residue, maintaining the conformation of 
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the remaining protein residues. The predicted changes in binding energies from this 
computational alanine scanning constitute the foundation for Robetta’s hot spot 
predictions [78].  Robetta provided the most accurate (indeed a perfect score) of the hot 
spots on TRAF6, with all three experimental hot spot residues in the structure having a 
predicted ΔΔG greater than 1 kcal/mol (Table 1). The Arg392 position is predicted to be 
a very active hot spot with a ΔΔG value much higher than the other two correctly 
predicted hot spots; from this prediction, one can infer that rational design around this 
residue is likely to give a better inhibitor of the TRAF6/RANK complex, since it 
contributes the most to binding of the RANK peptide. Values that are positive (or more 
positive) for the ΔΔG of the TRAF6/RANK complex indicate that a destabilization of the 
complex occurs when a residue is replaced by alanine; the other predictions do not show 
such a change in energy; hence they are not predicted to be hot spots. It is interesting to 
note that the next highest (and closest to 1.0 kcal/mol) ΔΔG value predicted by Robetta is 
the Phe410, with a value of 0.76 kcal/mol. This residue was later shown to be important 
to binding by the molecular dynamics results. 
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Num Residue int_id ΔΔG(complex) ΔG(partner) 
374 Val 1 0.36 1.04 
376 His 1 0.44 0.32 
392 Arg 1 3.76 1.51 
410 Phe 1 0.76 3.21 
412 His 1 0.4 2.61 
448 Glu 0 -0.03 -0.12 
450 Met 1 0.13 2.38 
453 Lys 0 -0.12 0.08 
456 Leu 1 0.48 1.34 
466 Arg 1 0.07 0.94 
469 Lys 1 0.62 -0.14 
471 Phe 1 2.05 1.65 
473 Tyr 1 1.73 1.8 
474 Val 0 0.07 0.43 
Table 1. TRAF6 Hot Spot predictions from Robetta. 
Num: residue number. Residue: three-letter code for amino acid. int_id: Binary 
descriptor of if a side chain of a residue is present within 4 Å of another 
partner’s atom (1) or not having a contact directly, but is buried upon binding 
(0); ΔΔG(complex): Prediction of binding free energy change upon mutation of 
alanine; ΔG(partner): Predicted change in stability of protein of the 
corresponding mutated partner complex upon subsequent alanine mutation. 
Residues highlighted yellow are biologically proven hot spots. If ΔΔG(complex) 
is greater than 1.0 kcal/mol, they are considered a hot spot by Robetta.  
 
 KFC2 did not have as successful of a prediction as Robetta. KFC2 is comprised of 
two models, KFC2a and KFCb, each having their own parameters. KFC2a offered no 
predictions for this structure, and KFC2b was adequate in providing correct hot spot 
predictions of Arg392 and Phe471, but provided two false positive results of Phe410 and 
His412. KFC2b also did not label Tyr473. Both KFC2 models label a residue a hot spot 
when the confidence of either method is a non-negative number (Table 2).  
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 Hotpoint’s predictions were identical (in terms of false positives and false 
negatives) to those from KFC2, predicting Arg392 and Phe471 correctly, but not labeling 
the residue Tyr473 and providing a false prediction of Phe410 as a hot spot (Table 3).  
The potential value on Arg392 was the highest among all of the residues that were 
considered interacting. Hotpoint did not predict His412 to be a hot spot, but did predict 
Met450 as one. This Met450 residue lies close to the aromatic residues of Phe471 and 
Tyr473, and is significantly buried. 
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Num Res KFC2-A Class KFC20-A Conf KFC2-B Class KFC2-B Conf 
374 Val 0 -1.78 0 -0.99 
376 His 0 -2.18 0 -0.98 
392 Arg 0 -0.37 Hotspot 0.15 
394 His 0 -1.9 0 -0.95 
410 Phe 0 -0.43 Hotspot 0.23 
412 His 0 -0.63 Hotspot 0.05 
448 Glu 0 -2.31 0 -0.98 
449 Ile 0 -2.39 0 -0.92 
450 Met 0 -1.42 0 -0.26 
451 Asp 0 -2.32 0 -0.96 
453 Lys 0 -1.77 0 -0.96 
456 Leu 0 -1.25 0 -0.83 
457 Leu 0 -2.37 0 -0.94 
458 Ala 0 -0.84 0 -0.76 
466 Arg 0 -1.8 0 -0.79 
468 Pro 0 -0.88 0 -0.8 
469 Lys 0 -0.79 0 -0.56 
470 Gly 0 -0.22 0 -0.46 
471 Phe 0 -0.17 Hotspot 0.28 
472 Gly 0 -0.38 0 -0.59 
473 Tyr 0 -0.87 0 -0.04 
474 Val 0 -1.24 0 -0.95 
475 Thr 0 -1.83 0 -0.99 
Table 2. KFC2 prediction of hot spots on TRAF6. 
Num: residue number. Res: three-letter code for amino acid. Model 
classification and predictions of two KFC models (A or B model); (Conf): 
Confidence of prediction. Residues highlighted in yellow (Arg392, Phe471, 
Tyr473) are experimentally proven hot spots. 
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Num Residue RelCompASA RelMonomerASA Potential Prediction 
374 Val 36.17 50.36 12.38 0 
376 His 29.78 35.89 18.13 0 
392 Arg 1.34 22.39 25.64 Hotspot 
410 Phe 1.94 11.86 28.55 Hotspot 
450 Met 1.76 6.09 33.49 Hotspot 
456 Leu 21.77 35.29 11 0 
457 Leu 61.09 62.37 7.59 0 
458 Ala 2.41 5.39 13.8 0 
468 Pro 37.32 74.16 4.79 0 
469 Lys 25.35 53.96 8.9 0 
470 Gly 0.19 29.14 12.76 0 
471 Phe 1.22 22.9 37.55 Hotspot 
472 Gly 0.45 35.78 16.16 0 
473 Tyr 7.52 27.91 17.22 0 
Table 3. Predictions of TRAF6 hot spots from Hotpoint. 
RelComp ASA: Relative ASA of complex structure. RelMonomer ASA: 
Monomer Relative ASA. Residues in yellow (Arg392, Phe471, Tyr473) are 
experimentally proven hot spots. 
 KFC2 and Hotpoint both were lacking in their prediction of Tyr473 as a hot spot, 
despite both methods having values that were close to the cutoff values to change the 
prediction form non-hot spot to hot spot. The confidence of Tyr473’s prediction in the 
KFC2b model very close to the threshold; this residue had the smallest negative value 
among the other residues in the list. The only reason Hotpoint’s prediction did not 
mention Tyr473 as a hot spot was due to the potential factor; the value was not greater 
than 18.0. The false positives from Hotpoint (residues Met450 and Phe410) stem from 
the relative high potential, and not from the accessible surface area metric. As was 
mentioned before, Phe410 and Met450 were in fact tested at the same time as the other 
residues, and were not proven to be hot spots [15]. This conclusion does not mean that 
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they have no contribution to the complex, but that they do not meet the experimental 
cutoff value of a hot spot. Since both programs scored the Phe410 and Met450 residue 
very close to a hot spot, both these residues should not be ignored as they will likely 
contribute to the binding, albeit not significantly (at least to the RANK peptide). 
2. Virtual Screening 
 In GOLD, the default scoring function is the GoldScore; this is comprised of four 
components from the equation: 
int_int___ vdwhbextvdwexthb SSSSf +++=  
 Where Shb_ext is the protein-ligand hydrogen bonding score and Shb_int is the 
internal hydrogen bonding of the ligand. Svdw_ext and Svdw_int are the scores arising from 
weak external and internal Van der Waals forces, respectively. The scores from the 
virtual screening approached an extreme value distribution (Figure 3) 
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Figure 3. Histogram of TRAF6 virtual screening results (GoldScores) from GOLD.  
 
The highest GoldScore was 75.18 and the lowest was 18.31. The average was 40.30 
for the GoldScore. 
 
3. Selection of Compounds for Biological Testing, and Biological testing 
 The technique described above resulted in 300 compounds for consideration for 
biological testing. The first round of selected compounds was limited in the number of 
compounds that were to be tested, and only seven compounds were selected for testing 
(Table 4). These first seven tested compounds were found to be not active when tested at 
100µM and 300µM (Figure 4).  
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Table 4. First set of selected compounds for biological testing.  
Test ID values were assigned from decreasing GoldScore from the list of 79 compounds. 
GOLD: GoldScore output from GOLD. logP: calculated log of octanol/water partition 
coefficient. All seven of these were shown to be inactive via GST pull-down assay. 
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Figure 4. GST-RANK pull down assay for first round of seven selected compounds.  
DP is the positive control decoy peptide, and C is the negative control (no peptide). 
 After discovery that the first set of compounds were not active, the docking 
results were examined once again, this time with emphasis on the Arg392/Phe410 
binding site. The reasoning was that it was this region (not the Phe471/Tyr473 region) 
that might be more significant to the binding of compounds to TRAF6. The second round 
of compounds were taken from the pool of 79 compounds, but compounds to be selected 
for the second round were those compounds that had a more favorable binding to this 
region. Twenty compounds were selected for the second round of testing (Table 5), 
(Table 6), and (Table 7) using the same technique as the first round of compounds, but 
were to only be tested at 200µM (Figure 5). While the concentration of the ligands was 
high, there does seem to be some reduction in the binding of the compounds SZB-40, 
SZB-45, and SZB-46. 
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Table 5. Second set of compounds to be tested. 
GOLD: GoldScore output from GOLD. logP: calculated log octanol/water partition 
coefficient. Test ID: assigned names from list of 79 compounds. 
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Table 6. Second set of biologically tested compounds (continued).  
GOLD: GoldScore output from GOLD. logP: calculated log octanol/water partition 
coefficient. Test ID: assigned names from list of 79 compounds. 
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Table 7: Second set of biologically tested compounds (continued).  
GOLD: GoldScore output from GOLD. logP: calculated log octanol/water partition 
coefficient. Test ID: assigned names from list of 79 compounds. SZB-40, SZB-45, 
and SZB-46 showed some activity. 
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Figure 5. GST-RANK pull down assay for first round of selected compounds.  
DP is the positive control decoy peptide, and C is the negative control (no peptide). 
Compounds 40, 45, and 46 appeared to have some activity. 
 
 Molecular Dynamics simulations 
 GROMACS simulations were run for 20 nanoseconds compound SZB-40, SZB-
46, and for the RANK peptide (as a control and comparison). SZB-40, which appeared to 
have the best binding score from GOLD, did not have as significant of a binding energy 
when compared with the RANK peptide (Figure 6). This figure shows the short range 
Lennard-Jones energy of the protein-ligand complex. The average energy of the run of 
SZB-40 was -177kJ/mol, while RANK had energy of -257 kJ/mol; standard deviations 
were 20.86 and 28.10 for SZB-40 and RANK, respectively. 
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Figure 6. Lennard-Jones energies for molecular dynamics simulations. 
TRAF6-ligand complex (kJ/mol) of SZB-40 (blue), SZB-46 (red), and RANK 
peptide (green) for the entire 20 nanosecond molecular dynamics simulation. 
Output of energies was performed for each trajectory, and the output was graphed 
in Excel. 
 
 The two simulations produced roughly similar RMSD values, the control RANK 
simulation deviating at an average of 0.239Å from their main chain, and the SZB-40 
RMSD equal to 0.196Å, indicating that the overall stability of the structure was not 
significantly affected by the ligands. The standard deviation of main chain of the 
structures was 0.0399 Å for RANK, 0.0288 Å for SZB-40.  
 The region of the 9,000 to 13,000 picoseconds (9 to 13 nanoseconds) is 
interesting, as it shows better energy values. Output of trajectories at every 2,000 
picoseconds was carried out for the entire simulation, in order to evaluate the differences 
that occur between SZB-40 and the TRAF6 structure throughout the MD run. The 
trajectory at 10 nanoseconds shows a very interesting conformation (Figure 7). It appears 
that the ligand has achieved pi-stacking with the aromatic residues Phe470, and there is 
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also a pi-stacking interaction to the Phe410 residue. There are hydrogen bonds to two 
points on the main chain of Gly469, similar to that of RANK. It is interesting to note that 
many portions of the MD simulation run showed the ligand on the side of TRAF6 closer 
to the Phe471 residue. This conformation was not possible in the GOLD 
screening/docking, as only the side chains are flexible; the GROMACS MD simulation 
shows a more favorable position to those that were seen from the GOLD docking. 
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Figure 7. Sample trajectory conformation at mid-point (10 ns) of MD simulation of 
SZB-40 (pink) and TRAF6 (green). Yellow dashed lines with numerical labels 
denote distances to neighboring aromatic groups. Hydrogen bonds to main chain 
atoms on Gly469 to SZB-40 are shown in unlabeled yellow dashed lines. This 
conformation was close to the average structure over the 9-11 nanosecond range, 
and it shows a more favorable pose to docked positions, with pi-stacking of both 
aromatic ends of SZB-40 to other aromatic groups on TRAF6. The distance from 
SZB-40 to Phe410 is 4.0 angstroms, and Phe410 was predicted as a hot spot by 
HotPoint and KFC2. 
 
 Another sample output was taken at the 12,000 picoseconds (12 nanoseconds), 
which is also in the region of lower energy. One would assume that this lower energy 
state would correspond to a more favorable docked position similar to that of the 10 
nanosecond point, and this is indeed the case (Figure 8.). This is similar to that of the 10 
nanosecond point, but there is additional hydrogen bonding to Gly471 (which lies in 
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between Tyr472 and Phe470. This state should have an even tighter binding to TRAF6, 
and this might explain why SZB-40 was shown to be active. 
 
 
Figure 8. 12 nanosecond sample trajectory of SZB-40 (pink) and TRAF6 (green). 
Yellow dashed lines denote distances to neighboring aromatic groups. Hydrogen 
bonds are shown in yellow dashed lines without distance labels. Note the more 
extensive hydrogen bonding to both Gly469 but also to main chain atoms on Phe471. 
This interaction is also more favorable to docked positions seen from GOLD. 
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4. LD50 Predictive QSAR Modeling 
 A histogram of the compounds shows a good distribution of values, and 
approaches an extreme value distribution (Figure 9). After the kNN-QSAR models were 
generated at various parameters, the predictive model with the best cross validated r2 (q2) 
had eight descriptors and were as follows:  logPWeighted, smallestRingSize, 
acceptorCount, ASAPolar, topologicalPolarSurfaceArea, chainAtomCount, atomCount, 
and hararyIndex. These descriptors are primarily associated with size, logP, and 
accessible surface area. The number of nearest neighbors for this highest rated model was 
three (k = 3), and this model had a q2 value of 0.324 in the training set, and a 
corresponding r2 of 0.6252 for the 385 compounds in the test set. The distribution of the 
actual versus predicted values can be seen when plotted (Figure 10). 
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Figure 9. Histogram of negative log of LD50 values (mol/kg) of 3472 compounds.  
The highest value was that of tetrachlorodibenzo-p-dioxin (TCDD), with a value of 
10.2, while the lowest was 6-methyl uracil, with a value of 0.29. The average value 
was 2.466. Data was transformed and graphed using Excel. 
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Figure 10. Actual vs. Predicted LD50 values from best kNN-QSAR model. 
 
5. Bioavailability Predictive QSAR Modeling 
 While the values for bioavailability were well distributed (Figure 11), the 
bioavailability model did not perform as well. There are 22 descriptors for this model, 
these were all generated from MOE, and they are as follows: randicIndex, FASA_H, 
PEOE_VSA_FPPOS, pmiY, vdw_vol, SMR_VSA2, Q_RPC-, PEOE_VSA_FPOL, 
PEOE_VSA-2, vsurf_HB2, PEOE_VSA+3, b_1rotR, carboRingCountOfSize, 
logDPHYS, SMR_VSA1, aliphaticRingCount, chi1v_C, a_ICM, SlogP_VSA0, 
BCUT_SMR_3, GCUT_SLOGP_2 mr, and BCUT_SLOGP_1. There are four nearest 
neighbors, and the q2 is 0.363177 for 414 compounds, and the r2 is 0.123 for 306 
compounds (Figure 12). 
37 
 
 
Figure 11. Histogram of 809 bioavailability values used in the predictive model.  
The data set has good distribution over the range of possible values with a very 
slight bias towards high values: the average value is 52.0 and median value is 54. 
Graph was generated in Excel. 
 
 
Figure 12. Actual vs. Predicted bioavailability values from kNN-QSAR model.  
This is the r2 test set, with 414 compounds. Values were taken from the output of the 
best quality model, and were graphed in Excel. The low quality of the data used in 
this model adversely affected the predictive quality of the model itself. 
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Discussion: 
1. Computational Hot Spot Predictions of TRAF6 
 The TRAF6/RANK pathway is typical of most biological cellular functions, in 
that a protein-protein interaction is required to retain functionality [79]. Broadly 
speaking, formation of protein-protein interactions necessitate particular contacts and 
interactions which form the foundation for almost all biological functions, most notable 
of these are events are signal transduction events. Protein-protein interactions are seen as 
having locally primed features optimal for the binding of their partners, and they form 
highly conserved and dense networked clusters contributing cooperatively to the 
complex’s stability [80]. The interaction sites of these protein-protein pairings are made 
up of surfaces that contain electrostatic and shape complementarity properties [81-84]. 
Protein-protein interactions can also be drastically influenced by the inherent properties 
of their residues, such as hydrophobicity and flexibility [82-86]. Some protein-protein 
interfaces have been described with relatively small areas, with surfaces as small as 1150-
1200 Å2  for structures such as complexes forming low-stability and short-lived regions. 
So called “standard-size” surfaces of interaction [87] fall into the region of 1600 Å2 (± 
400 Å2) and involve relatively small conformational fluctuations and side-chain 
movements upon forming said complexes[88]. “Large” interfaces involve 2000 to 4600 
Å2 , and  require significant, global changes in the interacting members, and are seen 
primarily in G-protein receptors and family members, as well as information processing 
elements of signaling proteins. Using the DMBL-EBI PDBePISA (Protein Interfaces, 
Surfaces and Assemblies) server [89], the TRAF6/RANK complex is shown to have a 
very small interface area, being only 557.8 Å2 in size. The TRAF6/CD40 complex 
(1LB6), has a slightly larger surface area, with 573.1 Å2. This means that the 
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TRAF6/RANK complex is very small and unstable, and very little changes in either 
structure are expected to occur when binding takes place.  
 The three methods used to predict hot spot residues used a variety of techniques, 
and each has been successful in other test sets of proteins. Robetta achieved a perfect 
score in its prediction of the TRAF6 residues, and in another study, correctly predicted 
79% of residues with a 1.0 kcal/mol cutoff (indicating they are in fact hot spots) with an 
error averaging to the value of 1.06 kcal/mol [78, 90]. While this method was the most 
successful in predicting hot spots of the TRAF6/RANK complex, there is one potential 
source of error in the implicit solvation model used by Robetta and for other predictions: 
hot spots that are mediated from water molecules can potentially compensate for 
particular alanine mutations, and can potentially give a false positive result. Since the 
waters were removed from this complex before submitting to Robetta, this was not an 
issue. 
 HotPoint is based on work that was done by Tuncbag et al. it uses primarily 
accessible surface area (ASA) and includes factors for conservation and pair-wise 
potentials of the residues to form an empirical model. This model has been recorded at 
70% accuracy, when using 150 residues from ASEdb as the training set; this accuracy is 
higher than many machine learning based methods [91]. This technique was implemented 
into a publicly available web server, also named HotPoint, where visitors can register and 
submit a job and easily visualize the output prediction on any compatible browser [52]. 
Accessibilities to the solvent for each residue are computed for each form (bound and 
unbound), and the energetic pair-wise potential contributions from the solvent were 
provided by Keskin et al [92]. If and only if the following two endpoints are satisfied: the 
relative ASA in complex is equal to less than 20%, and the summation of the potential for 
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a given pair is greater or equal to 18.0, then that residue is classified as a hot spot [52]. 
The mutation of solvent accessible surface area (ΔASA) when a complex is formed for 
two proteins has a high degree of correlation to the energy of solvation. This factor was 
previously identified to be highly predictive versus other factors towards that of the 
binding of protein partners [93]. The same group also developed a database from this 
technique, called HotSprint, and was successful in predicting hot spots on the p53 binder, 
Mdm2. An accuracy of 76% was achieved, which can out-compete many popular 
methods that rely on machine-learning approaches [94]. 
 KFC2 (Knowledge-based FADE and Contacts, by Darnell, Zhu, Page, and 
Mitchell [53, 95] ) uses a support vector machine (SVM) [96], machine-learning method 
to build two models, each of which are decision tree-based. Each model is built on two 
techniques: the first one is named K-FADE, it uses the size of a given residue and the 
specificity of its shape that are calculated by Fast Atomic Density Evaluation (hence the 
name FADE) [97], and K-CON uses the residue’s hydrogen bonds, chemical types, 
interface points, and intermolecular atomic contacts [54]. These features are combined to 
output an answer in binary form to the question of if a residue is a hot spot or not, and 
provide a corresponding confidence score with this binary prediction. KFC2 has two 
models trained on SVM: KFC2a and KFC2b. The KFCa model was shown to have 0.85 
as its rate of predicting hot spots correctly. This value was an improvement from the 
previous KFC method, as well as other predictions from HotPoint, Robetta, and 
FOLDEF, despite KFCa possessing a greater rate of incorrectly labeled hot spots than 
these competitors. KFC2b uses a total of seven features (overlapping two of the features 
from KFCa), and is seen to output a specificity greater than KFCa [53]. It is interesting 
that despite KFC2a’s higher reported sensitivity and accuracy when compared to KFC2b, 
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no hot spots were predicted for the TRAF/RANK complex with KFC2a. It is also 
interesting that while the KFC2a model predicted no hot spots on TRAF6, the KFC2b 
model appears to have had both a high true positive, and a higher false positive rate.  
 
2. Preparation and Analysis of Target Receptor 
 Selection of crystal structures 1LB5/1LB6 was necessary since both have the 
RANK/CD40 peptides bound to them. The remaining C-terminal 21 residues at the end 
of the crystal structure that are not included but exist in the TRAF6 sequence do not lie 
close to the RANK/CD40 binding site. The shortest distance from Thr501 to the RANK 
peptide is 16.4Å. Also, Thr501 ends a β-sheet, so the remaining residues of the structure 
are likely in a loop region that either interacts with the other loop regions in this area, or 
with the long helix that forms in the TRAF6 trimer (Figure13) 
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Figure 13. C-terminal Thr501 residue in TRAF6 1LB5 crystal structure (green).  
 
RANK residue shown in magenta sticks. This threonine residue lies at least 19 
angstroms to the RANK binding site; remaining residues on this tail are unlikely to 
have an effect on the binding site. 
 
 1LB5 was selected as the structure for which to do docking, since it contains the 
RANK peptide bound to TRAF6. [15]. While the TRAF6-CD40 complex of 1LB6 has a 
slightly higher resolution (1.80Å), it is very similar to 1LB5 (resolution of 2.40 Å). The 
RMS of the two structures (when superimposed) is only 0.294 Å, and this difference is 
mainly in the loop regions of the two structures. The only TRAF6 residue in the binding 
site that is significantly different in its conformation is the Arg392 residue (Figure 14). 
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Figure 14. Superimposed overlay of 1LB5 (green) and 1LB6 (blue) structures.  
 
Hotspot residues are displayed in sticks. Tyr473 and Phe471 are nearly identical in 
their conformation, while Arg392 is rotated significantly. 
 
3. Chemical Library Selection 
 The choice of MyriaScreen as the primary ligand screening set ensured that 
adequate chemical diversity was present in the virtual screening, while retaining good 
drug-like and lead-like structures. Additionally, MyriaScreen compounds are easily 
commercially available, making for easy procurement and testing of the selected 
compounds.  
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4. Virtual Screening 
 GoldScore fitness function was selected as the scoring function, as it has been 
created and optimized for small molecule docking into the prediction of ligand binding 
energy. GOLD has proven to be a more than acceptable program for various techniques 
when compared with other docking programs [98-100], and it has been shown to be 
capable of reproducing reliable docked conformations of ligands for many of my other 
projects. The program is able to run on a multi-core environment, which is favorable to 
other methods that are more computationally expensive.  
 
5. Processing of Results 
 The clustering of the GOLD results based on MACCS fingerprints removes 
similar compounds and increases the diversity of the pool of molecules by removing 
structurally similar compounds. Retaining the highest scoring representative structure of 
each cluster ensures the quality of the docked conformations is retained, but repetitive 
structures are discarded. This technique also ensures that the highest scoring 
representatives of each of the compounds is retained and selected as the best 
representative of the respective chemical core and binding pose.  
 
6. Selection of Compounds for Biological Testing 
 As for the selection of the final hits, the technique used here has been used in 
various other projects. The cluster centers were individually visualized by hand in 
PyMOL to maximize the potential of finding ligands that would prove to be active 
biologically. This higher scrutiny at this stage not only ensured that there was more than 
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adequate diversity in the final compounds; it confirmed that the compounds resided in the 
desired interaction site and therefore had a high potential of inhibiting the interaction 
with RANK. Also of note, our analysis was independent of the docking scores obtained; 
this made for our analysis to be more qualitative than quantitative.  
 
Flexible Docking of three active compounds 
 The three compounds that showed affinity (SZB: 40, 45, and 46) were submitted 
to a more rigorous GOLD docking, in which the ten closest residues to their original 
conformation were allowed to have their side chains be fully flexible; this process 
permits a deeper understanding of the potential interactions between the hits and TRAF6. 
For these docking jobs, GOLD was again used as the docking program, and the number 
of operations and population size of the genetic algorithm were doubled from the original 
virtual screening protocol. 
 Although the SZB-40 compound contains a ring structure that can gain stability 
by pi-pi stacking in between Tyr473 and Phe471, the flexible docking did not show such 
a conformation (Figure 15). Instead, there was main chain hydrogen bonding seen 
between Gly470 and His412. But the most significant difference in the side chains (due 
to the flexible docking) is seen in the Arg392 and Arg466 residues. There are two 
hydrogen bonded interactions to the Arg392 and this is stabilized by the pi-stacking of 
the terminal (non-chlorinated) benzene structure of SZB-40 to Arg466. The movement of 
these two structures between the original structures creates a more favorable pocket.  
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Figure 15. Flexible GOLD docking of SZB-40 (pink) to TRAF6 (green).  
Hydrogen bonds are shown as dashed yellow lines. This conformation show a weak 
pi-stacking to the Arg466 residue, and main chain hydrogen bonds to the Gly470 
and Phe471, but no significant interactions to the aromatic Phe410, Phe471, or 
Tyr473 residues.  
 
 
 SZB-45 was similar to SZB-40 in that it also had a moiety by which to mimic the 
proline structure on RANK in the pi-pi stacking interaction between the Tyr473 and 
Phe471 residues, but this conformation was not seen in the docking results (Figure 16). 
This structure had much more extensive binding to the Arg392 and Arg466 structures 
(from the highly charged sulfonamide region) at multiple locations on each of these 
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residues. There is also a hydrogen bonding interaction with the Asn467 main chain. 
There appears to be a pi-stacking interaction with the Phe410 moiety; this somewhat 
validates the prediction of Hotpoint and KFC2, which both predicted this residue as a hot 
spot. Robetta calculated this residue’s ΔΔG of the complex with a value of 0.76 kcal/mol. 
 
Figure 16. Flexible docking of SZB-45 (blue) to TRAF6 (green).  
Hydrogen bonds shown as dashed yellow lines. Main chain hydrogen bonding 
interactions are seen to Asn467 and side chain hydrogen bonds are seen to the 
Arg466 and Arg392 residues. There is also a good pi-stacking interaction with the 
Phe410 residue. 
 
 As for SZB-46, this conformation seems to have a better opportunity for pi-
stacking in between the two aromatic structures, and it also is stabilized by the two 
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arginine groups (Figure 17). Additionally, the hydrogen bonding interactions with the 
Gly470 are similar to that of RANK, and there are two hydrogen atoms on the Lys469 
structure that share hydrogen bonds with two different carbonyl regions of the SZB-46 
ligand. 
 
Figure 17. Flexible docking of SZB-46 (blue). Hydrogen bonds shown in yellow. 
This conformation shows side chain hydrogen bonds to Arf466, Arg392, and main 
chain bonds to Gly470 and Phe471. There is also a good pi-stacking interaction to 
Phe410. 
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7. Biological Testing 
 The GST-RANK pull down assay did manage to show an inhibition of three of 
the hits on the second round of testing, but as this method is more qualitative than 
quantitative, it is difficult to elaborate on the results beyond what is apparent from the 
Western blot. Further testing is required (preferably one that can be quantized) using 
another technique, possibly an ITC or luciferase assay. 
 
8. Molecular Dynamics simulations 
 The choice of GROMACS as the molecular dynamics (MD) package was an easy 
one, as GROMACS is very flexible and widely used software [64]. GROMACS has been 
shown to be much more efficient than other MD programs, and scales very well on large, 
parallel computing clusters [101]. It has been shown that the topologies resulting from the 
PRODRG server can deviate from simulations from GROMOS parameters, and 
reasonable configurations can be achieved using this method [102].  When the average 
back bone structure of the MD simulation is output from the MD simulation and then 
aligned to the original 1LB5 crystal structure, the RMSD is only 1.346Å, and this 
difference lies only in the loop regions, not in the β-sheet region (Figure 18). It is 
reasonable to assume that the stability of the β-sheet sandwich in TRAF6 is highly stable 
in the explicit water solvent used here. Hence, the GROMACS molecular dynamics 
method appears to be a good system on which to compare the result of this and future 
TRAF6 inhibitors. 
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Figure 18. Alignment of cartoon structures of MD simulation of TRAF/RANK.  
Average structure (backbone atoms) of results of MD simulation (blue), 1LB5 
structure TRAF6/RANK complex (green). RMSD of these structures is 1.346Å. The 
three hot spot residues are shown as sticks as a point of reference. Output for the 
simulation was prepared using Gromacs, and the structures were aligned using the 
“align” feature in PyMOL. 
 
9. LD50 Predictive QSAR Modeling 
 The large size of the dataset was a potential hindrance in the production of better 
models, but considering the variability of the data, the models were able to achieve a 
general prediction as to the magnitude of the endpoint which was attempted to be 
modeled. While most of the data is from oral testing of rats, the species and weights of 
these rats is not available. What is interesting (and perhaps contradictory to the previous 
statement) is that selecting only the less toxic compounds (removing the top 10% most 
lethal compounds from the data set) actually produced worse models than the one 
51 
 
presented here. The model presented includes highly lethal compounds like several forms 
of polychlorinated dibenzodioxins (dioxins), and the nerve agent O-ethyl-S-(2-
dimethylaminoethyl)-methyl-phosphonothioate (EDMM). Since lethality can manifest in 
different forms (inhibition of protein synthesis, mitochondrial damage, blocking of 
critical ion channels, DNA damage, to name a few), there are many different structural 
cores that are present in the dataset. These different structural cores and their 
corresponding mechanisms of lethality are likely creating confusion in the models. A data 
set that only contained ion channel disruptors is more likely to produce a good model of 
lethality, but would not be representative (or applicable) to other, more diverse 
compounds. Despite the variability of the data, logP is known to be a major factor in 
toxicity, as non-polar structures are much more likely to be metabolized and excreted (as 
well as be handled by the acidic gut) before their toxicity can become apparent. 
 
10. Bioavailability Predictive QSAR Modeling 
 The inconsistencies in the original data set definitely hurt the quality of the 
models generated, it is apparent that there is over fitting of the data, and the number of 
descriptors seen in the model (especially when compared with the LD50 model) backs this 
assumption up. Variability in the dosing, formulation, pharmacogenomics 
(polymorphisms in efficacy and other pharmacokinetic properties), health of the subjects 
and sampling error when recording the bioavailability data will all lead to a 
corresponding decrease of the quality of the models, and this is most likely what is seen 
here. It appears that such a complex endpoint in humans is difficult to model with simple 
tools, and classification schemes will likely lead to better predictive models. The strength 
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of using a kNN based model such as the one that was used here is that it is non-
parametric; there are no assumptions made on the distribution of the data set.  
 
Conclusion: 
 In this study novel inhibitors of the TRAF6/binding peptide interaction site are 
presented that were discovered through a rational design process incorporating various in 
silico techniques. From an initial set of 10,000 compounds, 26 of them were tested. Three 
of these 26 compounds were shown to be biologically active. These results validate the 
virtual screening and biological methodology described here, as well as validates the 
TRAF6/binding peptide interaction as a potential target for small molecule inhibition. 
 The results here lay the framework for future study of inhibition of the 
TRAF6/binding peptide interaction, and further study of the binding mechanism (either 
by crystallization of the inhibitors in complex with TRAF6, or by other biological 
experiments) will reveal means of optimizing the inhibitors for use in clinical settings. 
Future studies of the generation of TRAF6 inhibitors will surely benefit from additional 
assays for which to test the activity and mechanism of binding. Techniques such as a 
luciferase assay or isothermal titration calorimetry (ITC) would bolster the evidence of a 
possible inhibitor from the initial GST assay described above. Once a decent inhibitor has 
been found, optimization of the respective chemical groups can increase the binding 
affinity even further. While the TRAF6/binding peptide protein-protein interaction is a 
very valuable target, it is a difficult one. The binding site is not a prototypical pocket that 
is conducive to traditional drug design efforts, and the interaction site, despite being 
small for protein-protein interactions, is large for small molecule inhibitors to bind to. In 
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general, targeting protein-protein interactions are high-risk and high-reward, but the 
TRAF6/binding peptide interaction is beyond the exemplary target and has even higher 
potential value. Computational techniques such as the ones that I have outlined here (hot 
spot prediction, virtual screening, and molecular dynamics simulations) will help to 
ameliorate the risk involved by guiding the decisions throughout the drug design process. 
  Given that TRAF6 plays many essential roles in immunity and other diverse 
biological functions, TRAF6 inhibitors are most certainly in high demand. Not only will 
they serve to advance the understanding of the TRAF6 pathway, but has the potential to 
improve the lives of patients through controlling inflammation and treating a wide range 
of diseases, such as: osteoporosis, cancer-induced bone lesions and other bone diseases, 
postmenopausal osteoporosis, multiple myeloma, periodontitis, connective tissue 
destruction, bladder outlet obstruction, Paget’s disease, and viral infections [103-105]. On 
the front of cancer therapeutics, it has been postulated that TRAF6 inhibitors should be 
able to inhibit the spread of multiple myeloma and prevent bone loss (the most significant 
clinical manifestation of MM). These inhibitors will mean the inclusion of a new target 
for the treatment of cancer, and will be able to overcome resistance to chemotherapy 
[106]. There are still more questions as to the TRAF6 pathway, most notably the specific 
activation mechanism of TRAF6. It is unknown if TRAF6 is monomeric before 
recruitment to its receptors; additionally it is unclear if it is the TRAF6 oligomerization or 
the resulting conformational changes from oligomerization that guide the subsequent 
activation of TRAF6 [107]. These questions, as well as understanding how ubiquitination 
plays a role in TRAF6 activation, need to be answered to complete the puzzle. As the 
understanding of TRAF6 and its effectors continues to be understood, the use and affinity 
of TRAF6 inhibitors will prove to me more efficacious as our understanding improves. 
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